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บทคดัยอ่ 
วตัถปุระสงค์: เพื่อศกึษารูปแบบการสัง่ใชย้า สาเหตุของปัญหาที่เกี่ยวเนื่องกบั
การใช้ยาบรรเทาปวดอนุพนัธ์ฝ่ินและยาเสริมบรรเทาปวดในผู้ป่วยมะเร็งระยะ
สุดทา้ยที่รบัการรกัษาประคบัประคอง และความสมัพนัธร์ะหว่างปัจจยัทีอ่าจส่งผล
ต่อการเกดิปัญหาทีเ่กีย่วเนื่องกบัการใช้ยา วิธีการศึกษา: การศกึษาเชงิพรรณนา
เก็บข้อมูลย้อนหลงัจากเวชระเบียนผู้ป่วยและแบบบันทกึข้อมูลการเยี่ยมบ้าน
ผูป่้วยระหวา่งวนัที ่1 ตุลาคม 2558 - 30กนัยายน 2559 ส ารวจและประเมนิปัญหา
และสาเหตุทีท่ าใหเ้กดิปัญหาที่เกีย่วเนื่องกบัการใช้ยาองิตามเกณฑ์ The PCNE 
Classifications v.7.0 วิเคราะห์ข้อมูลโดยใช้สถิติเชิงพรรณนาและ Chi-square 
test ทีร่ะดบันัยส าคญั P-value < 0.05 ผลการศึกษา: จากผูป่้วยในทัง้สิน้ 35 ราย 
เป็นเพศชาย 21 ราย ( ร้อยละ 60.00) อายุเฉลีย่ 61.46 ±14.98 ปี โรคที่ไดร้บัการ
วนิิจฉัยมากทีสุ่ดคอืมะเร็งตบั (ร้อยละ 20.00) รูปแบบการใชย้ากลุ่มอนุพนัธุ์ของ
ฝ่ินในการควบคุมอาการปวดทัง้วันขณะนอนโรงพยาบาลที่พบมากที่สุดได้แก่ 
morphine MST (10) 1x2 pc พบ 5 ครัง้ (ร้อยละ25.00) ปัญหาทีเ่กีย่วเนื่องกบัการ
ใช้ยาขณะนอนโรงพยาบาลเฉลีย่ 1.17 ครัง้/ราย ซึ่งปัญหาทีพ่บมากที่สุด  ได้แก่  
Effect of drug treatment not optimal (16ครัง้, ร้อยละ 39.02) และพบลกัษณะ
ปัญหาที่เกี่ยวเนื่องกบัการใช้ยาเดยีวกนัดงักล่าวจากใบสัง่ยากลบับ้านเฉลีย่ 1.16 
ครัง้/ราย (12 ครัง้, ร้อยละ 54.55) การรบับรกิารแบบผูป่้วยนอกเฉลีย่ 1.30 ครัง้/
ราย และจากบนัทกึการเยี่ยมบ้านเฉลี่ย1.16 ครัง้/ราย สาเหตุของปัญหาส่วนใหญ่ 
ได้แก่ Inappropriate drug according to guidelines/formulary พบความสัมพนัธ์
อย่างมนีัยส าคญัทางสถติริะหว่างระดบัความปวดและปัญหาทีเ่กี่ยวเนื่องกบัการใช้
ยาขณะนอนโรงพยาบาล (P–value  = 0.046)  สรุป: พบปัญหาเกีย่วกบัการใช้ยา
ในผูป่้วยมะเรง็ระยะสุดทา้ย ซึ่งสะทอ้นความจ าเป็นในการจดัการปัญหาดา้นยาทีด่ ี
โดยให้เภสชักรมสี่วนร่วม เพือ่ลดปัญหาทีเ่กีย่วเน่ืองกบัการใชย้าจากสาเหตุหลกัที่
พบและพฒันาแนวทางการใช้ยาบรรเทาปวดและยาเสรมิบรรเทาปวดอย่างสม
เหตุผลในโรงพยาบาลต่อไป  
ค าส าคญั: ปัญหาที่เกี่ยวเนื่องกบัการใช้ยา, การดูแลแบบประคบัประคอง, มะเร็ง
ระยะสุดทา้ย,ยาบรรเทาปวด, รูปแบบการสัง่ใชย้า 
 
Abstract 
Objective:  To determine prescribing pattern on opioids analgesics and 
adjuvant medications among patients with last- stage cancer receiving 
palliative care. Drug related problems (DRPs) and their causes, and factors 
potentially associated with the DRPs were also investigated.  Methods:  In 
this retrospective descriptive study, patients with end- stage cancer were 
selected.  Data were collected from inpatient medical records, outpatient 
medical record and home visit record for 1 year.  That were explored and 
evaluated drug related problem by The PCNE classifications v. 7. 0 then 
summarized and analyzed by descriptive statistics and Chi-square test at a 
significance level of P- value < 0. 05.  Results:  There are 35 inpatients, the 
majority were male (21 cases or 60% of all patients) with an average age of 
61.46 ± 14.98 years.  The most diagnosed disease was liver cancer.  DRPs 
during in hospitalization were found with an average of 1. 17 DRPs per 
patient.  The most common DRP the effect of drug treatment not optimal 
(39.02% of all DRPs). The majority cause of DRPs was Inappropriate drug 
according to guidelines/formulary. At out-patient visits, DRPs were found with 
an average of 1. 30 DRPs per patient. In home visits, an average of 1.16 
DRPs per patient was found with most common cause of the effect of drug 
treatment not optimal.  Pain level was significantly associated with having 
DRP during hospitalization (P-value = 0.046). Conclusion: DRPs were found 
among patients with terminal cancer receiving palliative care. The findings 
emphasized optimal medication management with pharmacist involvement. 
To relieve DRPs, guidelines for opioid analgesics and adjuvant medications 
management should developed. Such improvement could lead to a rational 
drug use.  
Keywords:  drug related problem, palliative care, end- stage cancer, 
analgesics, prescribing pattern   
  
 
Introduction 
Cancer is one of the leading causes of death worldwide.In 
Thailand, cancer is the third cause of death. 1 Approximately 
64,000 new cancer cases were diagnosed and 30,000 deaths 
were reported annually.  An average of 160 deaths daily was 
estimated. The incidence rate of cancer in Thailand was about 
153.6 per 1 0 0 ,0 0 0  population. 2 Since metastatic cancer is 
incurable, the role of palliative care has been increasing 
especially among last-stage patients.  
In 2002, the World Health Organization defined last- stage 
patient care or palliative care as the care aiming at maintaining 
quality of life of both the patients facing any life- threatening 
illnesses and their family members. Palliative care focuses on 
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the suffering, either physical, psychological, social or spiritual, 
based on a holistic approach.  The care needs to be initiated 
as early as the diagnosis of the terminal illness, and carried 
through the end of the patient’ s life and beyond the grief on 
loss among family members.3  
When approaching the end of life, patients face distresses 
necessitating alleviation.  Physical distresses include pain, 
dyspnea, lethargy, loss of appetite, nausea, vomiting, 
constipation, insomnia and confusion. Given patients may face 
more than one physical distress simultaneously. 4 Opioid 
derivatives have been helpful in alleviating distressful 
symptoms in last- stage patients especially those with severe 
pain.  With their actions on specific pain receptors, opioid 
derivatives could inhibit pain through the ascending pain 
pathway.  Even with a promising pain relief, opioid derivatives 
are not free of some significant adverse effects including 
respiratory depression. Another side effect not always relating 
to dose of opioid derivatives is constipation.  This is because 
opioid derivatives decrease intestinal water reabsorption, 
secretion and motility.  
In selecting appropriate analgesics for end-stage patients, 
pain severity dictates drug choices.  In addition to pain relief, 
adjuvant medications for specific causes of pain are also 
recommended. For example, patients with neuropathic cancer 
pain are given tricyclic antidepressant such as amitriptyline 
and nortriptyline concomitantly with pain killers.  In last- stage 
cancer patients with dyspnea, benzodiazepines such as 
diazepam and lorazepam are recommended.5  
In an international study on prescribing pattern among 
cancer patients, strong opioid derivatives were prescribed in 
as high as 61% of the patients during the last three months of 
their lives. 6 In Thailand, the problems of opioid derivative use 
have been multi-facet.  Thailand has been recognized as the 
country with low use of morphine.  The patients in need of 
morphine are those with cancer, and severe toothache or 
headache.  Unfortunately, among 65%  of the patients who 
needed morphine, only 20%  of them received morphine 
prescription.  Since morphine is a schedule- 2 narcotics in 
Thailand, its distribution has always been subject to a strict 
legal scrutiny.  With no domestic production of opium in 
Thailand, all opioid derivatives have to be imported. All parties 
face challenges along the whole distribution process including 
complicate purchasing steps, delayed distribution, and supply 
running out due to the restriction on borrowing or exchanging 
products between hospitals.  Moreover, strict rules on opioid 
derivative use have feared healthcare providers to deal with 
the products.7  
With a relatively limited number of drug items in hospital 
formulary compared to higher level hospitals, community 
hospitals face the most troublesome morphine supply 
shortage.This usually causes the patients and family members 
time and expense to get a referral for opioid drugs at provincial 
hospitals.  Unfortunately, only a limited amount of prescribed 
drugs were allowed, for example, a one-week or one-month 
supply of regular morphine tablets and a 30- tablet supply of 
controlled-release morphine tablets. Patients with devastating 
stage of illness or unable to pay a visit to the provincial 
hospitals remained in pain with the shortage of opioid drug 
supply.8 
To alleviate the access problem, region 7 office of the 
regional healthcare system consisting of the four provinces of 
Konkaen, Mahasarakham, Kalasin and Roi-et has developed 
a program to enhance the access to opioid derivative 
analgesics for last- stage patients.  All four provincial hospitals 
have engaged in the program as the network nodes for all 
community hospitals in their provinces. Development included 
referral system for last- stage patients, pharmacist’ s 
performance on drug distribution and multidisciplinary 
teamwork in palliative care.  
Khaowong Hospital, a 60- bed community hospital in 
Kalasin province, is responsible for patients in the districts of 
Khaowong and Nakoo of Kalasin, and certain parts of districts 
of Bankaw, Kamcha- ee, and Dongluang of Mukdaharn 
province. End-stage patients in these areas have been under 
the continuous palliative care of Khaowong Hospital in their 
residential communities.  Under the provision of the center for 
continuous care for end- staged patients, a multidisciplinary 
team consisting of physician, nurse, pharmacist, public health 
technical officer and physical therapist, was formed in 2013. 
More end- stage patients had been taken care of since 2014. 
Despite an existing guideline for palliative care for the team to 
follow, certain problems remained especially drug related 
ones.  With no guideline to specifically handle drug related 
problems (DRPs)  among opioid analgesics and other drugs 
necessary for end- stage cancer patients, pain and distress 
management for these patients was insufficient.  Such 
shortcoming had had certain portion of patients suffered 
greatly.  
Based on a routine- to- research study at Khaowong 
Hospital, there had been an increase in the use of opioid 
ไทยเภสัชศาสตรแ์ละวทิยาการสขุภาพ ปี 13 ฉบับ 3, กค. – กย. 2561  113 Thai Pharm Health Sci J Vol. 13 No. 3, Jul. – Sep. 2018 
analgesics in patients with terminal cancer.9 As a result, more 
DRPs arising from these analgesics were inevitable.  These 
DRPs included disrupted prescriptions of opioid analgesics 
resulting in no supply of analgesics for continuous pain control 
(around- the- clock dosing)  and/or for breakthrough pain.  A 
problem of analgesics dosing not in agreement with pain level 
was also relatively prominent, if not prevalent.  For example, 
patients with a pain score of only 2 to 3 out of 10 were given 
morphine which is a potent opioid analgesics.  Patients also 
suffered from adverse effects of analgesics including 
constipation, dry mouth, and dry throat.  Other DRPs included 
the need for medications to relieve side effects caused by 
analgesics.  For example, laxative drug was not given to 
alleviate constipation caused by opioid analgesics.  
A study at Jaokunpiboonphanomtuan Hospital to examine 
the effect of pharmacist participation in providing 
multidisciplinary care to cancer patients found that the number 
of DRPs of 1.46 DRPs per patient at baseline was reduced to 
0. 47 DRPs per patient post- intervention. 10 Pharmacist 
involvement in the multidisciplinary team allowed for effective 
identification and dissolution of DRPs.  It was also found that 
patients and healthcare providers were satisfied with 
pharmacist participation in the care process.  It was obvious 
that there has been a relative lack of studies to determine the 
extent of DRPs of analgesics and related adjuvant 
medications in patients with terminal cancer requiring palliative 
care.  Causes of such DRPs were also not fully understood. 
This present study aimed to determine 1) prescribing patterns 
of analgesics and adjuvant medications in patients with 
terminal cancer, 2)  the causes of such DRPs, and 3) 
relationships between potential factors and the DRPs, at 
Khaowong Hospital. The findings could be useful in improving 
the guideline regarding analgesic management in the 
multidisciplinary team.  
    
Methods 
 
In this retrospective study, patient data from October 1, 
2015 to September 30, 2016, were collected medical records 
of in-patient, out-patient, and home healthcare visits. Patients 
were those with terminal cancer receiving palliative care 
provided by Khaowong Hospital and they were recruited into 
the study based the following inclusion criteria.  They needed 
to be diagnosed with terminal cancer, at least 18 years of age, 
receiving palliative care, and given at least one type of opioid 
analgesics and adjuvant medications available in Khaowong 
Hospital. These analgesics included 10-mg sustained release 
morphine sulfate tablets ( or MST) , morphine injection ( 10 
mg/amp. ) , morphine syrup (10 mg/5mL) , tramadol injection 
( 50 mg/ amp. ) , 50- mg tramadol capsule, and pethidine 
injection (50 mg/amp. ) .  Adjuvant medications were 0.5-mg 
lorazepam tablet, 2-  and 5-mg diazepam tablet, diazepam 
injection (10 mg/amp.), 10-mg nortriptyline tablet, and 10- and 
25- mg amitriptyline tablet.  Other medications included 
laxatives such as bisacodyl tablet, milk of magnesia, and 
lactulose.  To be eligible, the patient’ s medical records either 
from hard copy or electronic records (HosXP®)  needed to be 
sufficient for analysis. Patients were excluded if they received 
treatment modalities other than analgesics.  These treatments 
included physical therapy, acupuncture, and alternative 
medicine. All 63 patients in the registry of palliative care were 
verified for eligibility.  All eligible patients were subject to 
inclusion.  No sample size justification was performed since 
there was a small number of patients in the registry.   
 
Study instruments  
In terms of study instruments, a set of questionnaires was 
used to collect data of demographic information and 
medication use. Clinical status was also assessed as follows. 
Pain was measured using the numerical rating scale (Pain 
score; PS) and categorized into three levels, i.e., patients with 
severe pain (PS of 7 – 10 points) , moderate pain (PS of 4 – 
6 points), and mild pain (PS of 1 – 3 points).5 The patient’s 
performance was assessed using the Palliative Performance 
Scale (PPS) for Adult Suandok. Five dimensions of palliative 
performance included ambulation, activity/extent of disease, 
self-care, intake, and consciousness level.  The performance 
was categorized into stable (PPS of 70 - 100%) and terminal 
(PPS of 0 -  30%) , and those in between the two categories 
(PPS of 40 -  60%) . 11 DRPs were identified according to the 
Pharmaceutical Care Network Europe (PCNE)  classifications 
v.7.0.12 Treatment modalities and medication use were based 
on the clinical practice guideline for cancer pain (2013) of the 
Thai Association for the Study of Pain5 and clinical practice 
guideline of palliative care ( 2014)  of the Department of 
Medical Services, Ministry of Public Health.4 To identify DRPs 
and the related causes, pharmacist in the palliative care of 
Khaowong Hospital was responsible for the task with 
discussion with the expert clinical pharmacists to reach the 
sensible agreement.   
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Data collection  
Data of eligible patients on their last hospitalization during 
October 1, 2015 to September 30, 2016 were collected.  Data 
after discharge, to the out-patient and home healthcare visits 
were also collected.  This study was approved by the Human 
Ethics Committee of Mahasarakham University ( Issue No. 
19/2560, March 6, 2017).  
 
Data analysis  
Data of demographic and clinical status including gender, 
age, payment scheme, caregiver, diagnosed illnesses, co-
morbidities, and hospitalization days, were summarized using 
descriptive statistics.  Categorical variables were test for 
relationship using chi-square test.  Statistical significance was 
set at a confidence level of 95% (P-value < 0.05). All statistical 
analyses were performed using SPSS software program 
version 16. 0.  We tested the relationships between 
independent variables ( gender, age groups, co- morbidity 
groups, pain levels and PPS groups) and dependent variables 
(DRPs).   
   
Results  
 
Of the 63 patients in the registry, 35 of them were eligible. 
Of the 28 patients excluded, 14 were diagnosed with diseases 
other than terminal cancer, nine were not hospitalized within 
the study duration, 3 did not have in-patient medical records, 
1 was younger than 18 years old, and 1 was treated with 
alternative medicine.  
The majority of the 35 participants were men (60.00%) 
(Table 1) .  Their age was 61.46  14.98 years by average. 
Most of them had universal coverage payment scheme 
(80.00%)  and all of them had caregivers.  The majority had 
liver cancer (20.0%)  and had at least one co-morbid disease 
(45.71%)  with 25.71% having anemia.  Type of pain was 
assessed in 14 patients ( 40. 00% 0 while pain level was 
evaluated in 28 patients (80.00% ) .  Twelve of 28 patients 
(42.86%)  were found to have severe pain (PS of 7 –  10 
points) .  PPS was assessed in 19 patients (54.29%) .  The 
majority (12 of 19 patients, or 63.16%)  were within the PPS 
of 40 –  60% .  Two patients had dyspnea.  Average 
hospitalization was 4. 49 days per patient.  There were ten 
patients who had out-patient visits after the discharge; while 
six patients had home healthcare visits.  
  
 Table 1  Demographic and clinical status information of the 
participants (N = 35).  
Patient information No. (%)  
Gender  
Male  21 (60)  
Female 14 (40) 
Age (mean = 61.46 ± 14.98 yrs)     
18 – 60 yrs 25 (71.43) 
61 yrs or older  10 (28.57) 
Payment scheme  
Universal coverage  28 (80) 
Civil servant scheme  7 (20) 
Marital status  
Married  34 (97.14) 
Single 1 (2.86) 
Diagnosed illnesses 
Liver cancer 7 (20.00) 
Lung cancer 6 (17.14) 
Bile duct cancer 5 (14.28 
Colon cancer 4 (11.42) 
Cervical cancer  2 (5.17) 
Other* 11 (31.43) 
Number of co-morbid disease  
0 19 (54.29) 
1 9 (25.71) 
2 5 (14.28) 
3 or more 2 (5.71) 
Pain level based on pain score (PS) (n = 28)  
Severe pain (PS of 7 – 10 points) 12 (42.86) 
Moderate pain (PS of 4 – 6 points) 8 (28.57) 
Mild pain (PS of 1 – 3 points) 5 (17.86) 
No pain (PS of 0 points) 3 (10.71) 
Palliative performance score (PPS) and level (n = 19)  
Stable (PPS of 70 - 100%)  3 (15.79) 
Middle (PPS of 40 - 60%)  12 (63.16) 
Terminal (PPS of 0 - 30%)  4 (21.05) 
Number of hospitalization days  
1 - 5  25 (71.43) 
6 or more days  10 (28.57) 
Types of discharge  
With physician permission   24 (68.57) 
Treatment denied  6 (17.14) 
Referral to other hospital  5 (31.42) 
a Other kinds of cancer: one case (2.85%) for breast cancer, gastric cancer, lymphnode cancer, 
muscle cancer, gallbladder cancer, brain cancer, saliva gland cancer, ovarian cancer, intestinal 
cancer, adrenal gland cancer, and urinary bladder cancer. 
  
Prescribing patterns during hospitalization and after 
discharge  
Of the 35 patients hospitalized, 20 of them were 
prescribed around- the- clock dosing of analgesics for 
continuous pain control ( Table 2) .  The most prescribed 
around- the- clock opioid analgesics were 10- mg morphine 
tablets (or 10 mg MST) 1x2 pc (5 of 20 patients, or 25.00%). 
For breakthrough pain, the most prescribed analgesics were 
morphine injection (3 mg iv prn q 4 hr)  (7 of 25 patients, or 
25.92%). For adjuvant medications, lorazepam was prescribed 
in 9 of 35 patients (25.71%).  
In terms of medication adjustment, of a total of 20 
adjustments, frequency adjustment was found the most ( 1 1 
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adjustments or 55.00%) .  For example, morphine injection 3 
mg iv q 6 hr was changed to morphine injection 3 mg iv q 4 
hr.  Dose adjustment was done two times ( 10. 00% ) .  For 
example, morphine injection 3  mg iv q 4  hr was changed to 
morphine injection 10 mg iv q 4 hr.  
 
 Table 2  Prescribing patterns during hospitalization and at 
discharge (N = 35).  
Prescribing patterns  
of opioid analgesics    
No. % 
 
1) During hospitalization  
 Opioid analgesic prescription for continuous control (around-the-clock dosing)  
No 15 42.86 
Yes  20 57.14 
Dosing regimens prescribeda 
Morphine MST (10 mg tab) 1 x 2 pc 5 25.00 
Morphine MST (10 mg tab) 1 tab q 12 hr 3 15.00 
Morphine injection 3 mg iv q 6 hr 2 10.00 
Morphine injection 4 mg iv q 6 hr 2 10.00 
 Opioid analgesic prescription for breakthrough pain 
No 9 25.71 
Yes 26 74.29 
Dosing regimens prescribedb 
Morphine injection 3 mg iv prn q 4hr 7 25.92 
Morphine injection 3 mg iv prn q 6 hr 4 14.81 
Morphine injection 3 mg iv prn q 8 hr 4 14.81 
 Adjuvant medications 
No 25 71.43 
Yes 10 28.57 
Dosing regimens prescribed 
Lorazepam (0.5 mg tab) 1 x hs 8 88.89 
Lorazepam (0.5 mg tab) 2 x hs 1 11.11 
   
2) At discharge    
 Opioid analgesic prescription for continuous control (around-the-clock dosing) 
No 16 45.71 
Yes 19 54.29 
Dosing regimens prescribedC 
Morphine MST (10 mg tab) 1x3 pc 5 27.78 
Morphine MST (10 mg tab) 1 tab q 12 hr 2 11.11 
Morphine injection 2 mg iv prn q 4 hr.  1 5.55 
Morphine injection 5 mg iv prn q 6 hr. 1 5.55 
 Opioid analgesic prescription for breakthrough pain 
No 14 40.00 
Yes 21 60.00 
Dosing regimens prescribedd 
Morphine syrup 3 mL q 2-4 hr. 3 21.43 
Morphine injection 3 mg iv prn q 4 hr 2 14.28 
Morphine syrup 2 mL q 2-4 hr 1 7.14 
 Adjuvant medications  
No 24 68.57 
Yes 11 31.43 
Dosing regimens prescribede 
Lorazepam (0.5 mg tab) 1 x hs 8 72.73 
Nortriptyline (10 mg tab) 1 x hs 1 9.09 
a Other dosing regimens prescribed for continuous pain control during hospitalization included morphine  6 mg iv q 6 hr, morphine 4 
mg iv q 8 hr, morphine  4 mg iv q 12 hr, MST 10 mg 1 tab q 8 hr, MST 10 mg 2 x 2 pc, with one prescription each.  
b Other dosing regimens prescribed for breakthrough pain during hospitalization included morphine  2 mg iv prn q 4 hr, morphine  3 
mg iv prn , tramadol  50 mg iv prn q 8 hr, pethidine  25 mg iv q 6 hr, morphine syrup 3 ml prn q 2-4 hr, morphine syrup 5 ml prn 
q 2 - 4 hr, and morphine syrup 2.5 ml prn q 2 - 4 hr, with one prescription each.  
c Other dosing regimens prescribed for continuous pain control at discharge included morphine 5 mg iv prn q 8 hr, morphine  10 mg 
iv prn q 4 hr., tramadol (50) 1x3 pc, MST (10) 1 tab q 8 hr, MST (10) 4 tab q 12 hr, MST (10) 9 tab q 8 hr, and MST (10) 1x2 
pc, with one prescription each.  
d Other dosing regimens prescribed for breakthrough pain at discharge included morphine syr. 5 ml prn q 2 hr, morphine syrup 20 
ml q 2 - 4 hr, morphine syrup 2 ml x 2 pc, and morphine injection 2 mg iv prn q 4 hr, with one prescription each.  
e Other adjuvant medicatons prescribed at discharge included lorazepam 0.5 mg 2 x hs, and diazepam 5 mg iv prn, with one 
prescription each.  
 
In terms of medications prescribed at discharge, 19 of 35 
patients were given around- the- clock analgesics (54.29%) . 
The most prescribed analgesic regimen was morphine MST 
1 0  mg 1  tab X 3 pc (5 of 19 patients, or 26.32%) .  For 
breakthrough pain, analgesics were prescribed in 14 patients 
(40.00%) where morphine syrup 3 mL q 2 - 4 hr was the most 
prescribed regimen (3 of 14 patients, or 21.43%). A regimen 
of morphine syrup 5 mL prn q 2 hr was also prescribed. It was 
found that 11 patients were given adjuvant medications at 
discharge where a regimen of lorazepam 0.5 mg tablet 1 x hs 
was prescribed the most (8 of 11 patients, or 72.73%). 
After discharge, 10 of 35 patients (28.57%)  returned for 
out-patient visits with an average of 2.5 visits per patient. For 
pain level, four patients were evaluated and all had a severe 
pain (PS of 7 – 10 points). Only three patients were assessed 
for palliative performance.  One patient had a PPS score of 
90% at hospitalization which decreased to 60% at discharge; 
while that of another patient decreased from 40% to 30%.  
After discharge, 9 of 10 patients returing for out-patient 
visits were prescribed around- the- clock analgesic regimen 
(90.00%) .  Prescribed regimens included morphine MST 1 0 
mg 1 tab  q 8 hr and morphine injection 10 mg iv q 4 hr. For 
breakthrough pain relief, four patients were given analgesics 
(40.00%) , such as morphine syrup 2 ml prn and morphine 
injection 10 mg iv q 4 hr.  Regimen adjustment was found in 
two patients; one with medication change and another with 
dose change.  Adjuvant medication was prescribed only for 
one patient with the regimen of lorazepam tab 0.5 mg 1 x hs. 
In terms of adverse effects, two patients experienced 
constipation.  
After discharge, six patients were followed up with home 
healthcare visits with an average of 1.16 visits per patient. 
At home visits, severe pain (PS of 7 –  10 points)  was found 
in four patients, moderate (PS of 4 – 6 points) and mild (POS 
of 1 –  3 points)  in one patient each.  Palliative performance 
was evaluated in all six patients where three patients were in 
the three in ternal level (PPS of 0  -  30%)  while the other 
three were in the level between stable and terminal level (PPS 
of 40 –  60% ) .  Various distresses were found including 
restlessness, slurred speech, hematuria, confusion and 
weakness.  Few patients self- adjusted dose of opioid 
analgesics.  
 
Drug related problems and associated causes   
During hospitalization, 41 DRPs were found with an 
average of 1. 17 DRPs per patient.  According to the 
Pharmaceutical Care Network Europe (PCNE)  classifications 
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v.7.0, the most found DRP was P1.2 Effect of drug treatment 
not optimal (P1.2) (16 of 41 DRPs, or 39.02%) (Table 3). The 
most found cause of such DRP was C1.1 Inappropriate drug 
according to guideline/ formulary.  For example, patients with 
persistent pain were not given around- the- clock dosing of 
opioid analgesics and patients with breakthrough pain were 
not given rescue opioid painkiller injection.  
 
 Table 3   Drug related problems (DRPs)  and associated 
causes during hospitalization according to PCNE v.7.0 (N = 41).   
Problem 
code 
No. (%) 
Cause 
code 
No. (%) Example of DRP causes 
P1.2 16 (39.02) C1.1 7 (43.75) - Patients with persistent pain were not given around-the-
clock dosing of opioid analgesics.  
- Patients with breakthrough pain were not given rescue 
opioid painkiller injection. 
C8.2 4 (25.00) - Patients experienced sedation (sedation score of 3) after 
morphine injection.  
- Patients experienced breakthrough pain since no 
around-the-clock analgesic drug was prescribed.  
C3.3 2 (12.5) - Patients with persistent pain, but was given morphine 
injection q 6 hr which was not adequately frequent.  
- Patients were unable to control pain after morphine 
injection and the frequency of analgesic drug was not 
adjusted according to pain level.  
C6.2 2 (12.5) - Around-the-clock morphine injection was prescribed, but 
was given PRN as recorded by the nurse.  
- Uncontrolled pain and analgesic drug administration was 
recorded as less frequently than prescribed (4 mg iv q 8 
hr).  
C2.1 1 (6.25) - Patients were unable to swallow and needed NG tube 
but MST should not be splitted, ground or chewed to 
avoid a loss of therapeutic effect. 
C3.1 1 (6.25) - Dosage of analgesics was too low and breakthrough 
pain frequently occurred. 
C3.2 1 (6.25) - Dose of morphine syrup was more than 10% of the 
around-the-clock dose.  
P2.1 8 (19.51) C1.8 7 (87.5) - Patients experienced constipation from MST but laxative 
drug was not prescribed.  
C8.2 1 (12.5) - Patients experienced constipation from MST and the 
symptom persisted despite milk of magnesia was given.  
P3.2 6 (14.63) C3.4 2 (33.33) - Physician prescribed MST 1 tab q 4 hr.  
C8.1 2 (33.33) - With no assessment after morphine injection, 
effectiveness of PRN morphine was not known.  
C8.2 1 (16.66) - Detail of morphine syrup administration was not 
recorded. 
- Morphine injection was changed to MST by physician, 
but the dose was as high as 230% of usual dose and 
no assessment was done after regimen adjustment.  
C5.1 1 (16.66) - Senokot® was prescribed but the item was not available 
in the hospital.  
P1.3 5 (12.20) C1.5 
 
5 (100.00) - Both morphine injection and morphine syrup were 
prescribed concomitantly.  
- Pethidine was prescribed concomitantly with MST.  
P1.1 4 (9.76) C1.1 3 (75.00) - Around-the-clock analgesic drug was not prescribed.  
- Breakthrough pain was poorly controlled, but no dose 
adjustment was made.  
C3.1 1 (25.00) - Morphine injection 3 mg prn q 8 hr was given but pain 
persisted (pain score of 10/10 points). Breakthrough 
pain also occurred.   
P1.4 2 (4.88) C1.1 1 (50.00) - Pain persisted but analgesic drug was not prescribed.  
C6.4 1 (50.00) - Breakthrough pain occurred, but morphine administration 
was not recorded by the nurse.  
 
After discharge, there were 22 DRPs among 19 patients 
prescribed analgesic medications with an average of 1. 16 
DRPs per patient (Table 4) .  The most found DRP was P1.2 
Effect of drug treatment not optimal ( 1 2  of 22 DRPs, or 
55.45%) with the cause of C1.1 Inappropriate drug according 
to guideline/ formulary.  For example, patients had persistent 
pain but no morphine injection was prescribed for continuous 
pain control, and no prescription of morphine syrup for 
breakthrough pain. The second most DRP was P1.4 Untreated 
indication (6 of 22 DRPs, or 27.28%) with the cause of C1.1 
Inappropriate drug according to guideline/ formulary.  For 
example, with a dyspnea score of 8/10, Berodual®l nebulizer 
was prescribed during hospitalization but not for discharge. 
Other noticeable DRPs were P1. 3 Unnecessary drug 
treatment, P1.1 No effect of drug treatment/ therapy failure, 
and P3.2 Unclear problem/complaint.  
 
 Table 4   Drug related problems (DRPs)  and associated 
causes after discharge according to PCNE v.7.0 (N = 22).  
Problem 
code 
No. (%) 
Cause 
code 
No. (%) Example of DRP causes 
P1.2 12 (54.55) C1.1 12 (100.00) - Morphine syrup was not prescribed for 
breakthrough pain.  
- Pain was persistent but morphine injection was 
not prescribed.  
P1.4 7 (31.82) C1.1 7 (100.00) - No morphine injection or MST for continuous 
pain control was prescribed.  
- The patient denied hospitalization, and no 
analgesics were prescribed at discharge.  
- Patient had a dyspnea score of 8/10, but no 
morphine injection was prescribed.  
- With a dyspnea score of 8/10, Berodual® inhaler 
was prescribed during hospitalization but not at 
discharge.  
P1.1 1 (4.55) C7.8 1 (100.00) - Patient was unable to receive morphine since no 
caregiver to administer the injection.  
P1.3 1 (4.55) C1.5 1 (100.00) - MST, Morphine injection and morphine syrup 
were prescribed concomitantly.  
P3.2 1 (4.55) C3.2 1 (100.00) - Dose of morphine syrup was 20% higher than 
usual around-the-clock dose, with no drug effect 
known.  
 
Among patients who had out- patient visits after 
discharge, 13 DRPs were found with an average of 1.30 DRPs 
per patient.  The most found DRP was P1 . 2  Effect of drug 
treatment not optimal (5 of 13 DRPs, or 38.46%)  with e the 
cause of C1. 1 Inappropriate drug according to 
guidelines/ formulary.  For example, no morphine syrup for 
breakthrough pain and C1. 5 Inappropriate duplication of 
therapeutic group or active ingredient since pethidine injection 
was prescribed as the first choice instead of morphine 
injection. The second most DRP was P2.1 Adverse drug event 
occurring ( 3 of 13 DRPs, or 23. 07% ) .  For example, 
constipation with the cause of C1 . 8  Synergistic/ preventive 
drug required and not given where laxative was not prescribed 
to prevent constipation caused by morphine.  In addition, the 
DRP of P3. 2 Unclear problem/ complaint with the cause of 
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C5.2 Prescribing error, where administration method was not 
specified in the medical record by physician.  
 
Among patients who were followed up by home 
healthcare visits, 7 DRPs were found with an average of 1.16 
DRPs per patient.  The most found DRP was P1 . 2  Effect of 
drug treatment not optimal (3 of 7 DRPs)  with the cause of 
C1 .1  Inappropriate drug according to guidelines/ formulary (1 
of 7 DRPs)  where no alagesic medication was prescribed for 
breakthrough pain.  The DRP of P2. 1 Adverse drug event 
occurring was found where the symptom of nausea and 
vomiting cause by morphine MST was so severe that the 
patient could not take the drug. The DRP of P1.1 No effect of 
drug treatment/ therapy failure was found with the cause of 
C7.5 Patient administers/uses the drug in a wrong way.  This 
was because the patient’ s relative had crush or ground 
morphine MST so that the drug was ineffective to relieve the 
pain. Four DRPs in four patients were solved and recorded by 
investigating pharmacist providing home healthcare service by 
consultation with involving physicians and nurses.  These 
DRPS included prescribing pattern adjustment such as 
changing dosage regimen to be suitable for administration and 
advising the patient to seek pain re-assessment at the hospital 
(Figure 1).  
 
 
 
 Figure 1  Drug related problems (DRPs)  and associated 
causes found in home healthcare visits.  
 
 
In terms of relationships between having DRP and various 
factors (age, gender, co-morbidity, hospitalization days, pain 
levels and palliative performance levels) , there were no 
statistically significant relationships either during 
hospitalization or home healthcare visit except having DRP 
during hospitalization and pain levels (P-value = 0.046) (Table 
5).  
 
 T a b l e  5   Relationships between having drug related 
problems (DRPs) with various factors  
Variables  P-value* 
Having DRP during 
hospitalization 
Age (< 60 yrs, ≥ 60 yrs) 0.164 
Gender  0.127 
Co-morbidity (yes/no) 0.589 
Hospitalization days (≥ 5, ≥ 6 days) 0.478 
Pain levels (0, 1–3, 4-6, 7-10 points)    0.046 
Palliative performance levels (0-30%, 40-
60%, 70-100%)   
0.197 
   
Having DRP during home 
healthcare visit 
Age (< 60 yrs, ≥ 60 yrs) 0.164 
Gender  0.486 
Co-morbidity (yes/no) 0.478 
Hospitalization days (≥ 5, ≥ 6 days) 0.331 
Pain levels (0, 1–3, 4-6, 7-10 points)    0.526 
Palliative performance levels (0-30%, 40-
60%, 70-100%)   
0.197 
 * Chi-square test.   
 
Discussions and Conclusion  
 
Our study in end-stage cancer patients receiving palliative 
care found that most of the patients were male, and with 
severe pain and moderate level of palliative performance. 
More than 50% of the patients requiring opioid analgesics 
were given the drugs. Prescribing patterns were diverse 
among patients. Drug related problems (DRPs) during 
hospitalization were also diverse with those associated with 
drug selection as the most frequently found DRP. A given 
DRP could be associated with many causes. In addition, 
unclear problems were found left with no follow-up 
assessment. For example, with no follow-up assessment on 
pain level, effectiveness opioid analgesic was not known and 
further regimen adjustment could not be made.  
In terms of opioid analgesic medications, morphine was 
prescribed more frequently than other opioid derivatives. This 
finding was consistent with the study of Erlenwein and 
colleagues13 With various doses of morphine found in our 
study, 20 mg per day was the most prescribed dose during 
hospitalization. This dosage of morphine was similar to the 
one found in the study of Suecharoen and colleagues.14 It has 
been known that opioid overdose could cause death. The 
dose of opioid derivative of more than 20 mg per day was 
associated with a higher risk of overdose-related death than 
the lower dose.15 In our study, no sign of opioid overdose that 
could lead to death.  
In terms of palliative performance level and the opioid 
analgesics, the study of Sathornviriyapong and co-workers 
found that the doses either higher or lower than 30 mg 
morphine-equivalent dose per day was not associated with 
death among patients with terminal cancer receiving palliative 
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care.16 This seems consistent with our study where different 
doses of opioid analgesics were not associated with the 
change of palliative performance. In other words, among 
patents followed up at the out-patient visit, their palliative 
performance decreased regardless of the morphine doses.  
In terms of factors affecting morphine dose adjustment, a 
study with retrospective data review of Miura and colleagues 
(2014) found that dyspnea, age of less than years, and 
morphine dose of less than 50 mg per day were associated 
with the increase in morphine dose.17 In our study, we tried to 
assess dyspnea but found that assessment of dyspnea was 
rarely performed and recorded. In the future, more dyspnea 
assessment could be highly useful for opioid derivative 
analgesic dose adjustment.  
DRPs found in our study were relatively similar to a 
previous study10, where the most found DRP was Effect of 
drug treatment not optimal with the cause of the absence of 
around-the-clock analgesic prescription. Other causes of this 
DRP included only symptomatic rescue medications 
prescribed which left the patient’s pain poorly controlled and 
allowed breakthrough pain to occur despite having pain 
control medication. It was also found that the frequency of 
morphine administration was less than optimal. For example, 
morphine 3 mg iv q 6 hr was results in an inadequate pain 
control length since morphine offers 2 – 4 hours of pain 
suppression. In addition, dosage adjustment was suboptimal. 
Mostly frequency of administration, rather than dose 
adjustment according to pain level, was carried out. As a 
result, the dose of morphine was too low for the patient’s pain 
level.  
The most frequently found opioid related adverse effect 
during hospitalization was constipation. Constipation was a 
frequent and dose-independent effect of opioid derivatives. It 
is preventable with laxatives. However, in our study, among 
patients with constipation associated with opioid derivatives, 
laxative drugs were not given. However, in few patients, 
constipation persisted despite laxative use. These cases of 
persistent constipation could be due to the patient’s 
physiological and behavioral factors. Since data of adverse 
effects were under recorded, the extent and severity of 
undesirable effects of opioid derivatives could be 
underestimated. The data of adverse effects of opioid 
analgesics were crucial for patient compliance to the drug. 
Patients could face nausea and vomiting symptom from 
morphine that is so severe that they could not continue the 
drug. This cause the DRP of No effect of drug 
treatment/ therapy failure. Therefore, a progressive follow-up 
to seek adequate information of opioid derivatives use and 
their adverse effects should be enforced and promoted. This 
information included but not limited to sedation score to 
assess opioid overdose. Other side effects of opioids to 
monitor were urinary retention, dry mouth, dry throat, nausea, 
and vomiting. Providing information regarding adverse effects 
of opioid derivatives could alleviate anxiety and enforce 
confidence associated with drug use among these patients.  
Deviations of drug administration during hospitalization 
were found in our study. These deviations usually resulted in 
giving doses lower than prescribed. The finding could be 
useful for multidisciplinary team to improve the process 
together.  
The absence of necessary prescriptions in some patients 
after discharge was a relatively substantial problem. With no 
necessary medications at home, disrupted care could be a 
result. In addition, drug dosage form inappropriate for given 
patients could bring about a problem. For example, some frail 
patients prescribed morphine injection may need a caregiver 
to administer the drug. With poor understanding, the caregiver 
could administer inappropriately and pain could not well 
controlled. To make the problems worse, the hospital lacked 
resources to help the patients administer the drug such as 
syringe driver. Poor analgesic administration could lead too 
poor control on pain and other physical distresses such as 
dyspnea.  
From these findings, there is a room for improvement of 
the hospital to acquire materials and devices necessary for 
proper drug administration such as syringe driver for 
continuous infusion. Hospital formulary could be improved by 
adding analgesic dosage form more convenient self-care such 
as fentanyl transdermal patch for patients difficulty swallowing. 
For patients followed up at the out-patient visits, a larger 
proportion of them were given around-the-clock opioid 
derivative analgesics than when hospitalized or discharged. 
DRPs at out-patient visits were similar to those during 
hospitalization and at discharge especially Effect of drug 
treatment not optimal, and unclear direction. The investigator 
had a discussion with the multidisciplinary team for further 
solutions.  
For home healthcare visits, fewer patients were followed 
up by the procedure. This could be a result of unclear or 
nonspecific guideline on home visit. In addition, since these 
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patients were in their terminal stage of life, some of them 
passed away in a very short period of time that an urgent 
follow-up could not be made.  
Among these home visits, like hospitalization and out-
patient settings, the DRP of Effect of drug treatment not 
optimal was also found to be prominent. However, the causes 
of the problem were different from those settings and more 
factors were involved. For example, caregiver’s 
misunderstanding on MST administration led to crushing or 
grinding the MST tablet. Home follow-up visit with pharmacist 
in the multidisciplinary team could help identify and solve 
DRPs in these patients with end-stage cancer. Previous 
studies revealed that multidisciplinary palliative care 
consultation team involving prescription and administration 
could help relieve DRPs.11,16  
The assessment on pain level found in this study was 
inadequate since fewer patients were assessed for pain; some 
were assessed only during hospitalization. In addition, since 
specific types of pain were not thoroughly evaluated, 
medications suitable for specific causes of pain could not be 
prescribed. This was evident as adjuvant medications were 
prescribed in a very low portion of patients. Comprehensive 
pain control could not be achieved.  
Like pain assessment, palliative performance level was 
also assessed in a small fraction of patients, mostly done 
during hospitalization. This inadequate assessment made 
adjustment on drug dosing and administration adjustment 
more difficult, if not impossible. For example, administration 
problem persisted in patients with swallowing problem who 
were given MST tablet.  
In our study, having DRPs during hospitalization was 
significantly associated only with pain level, not gender, age, 
palliative performance level, or co-morbidity. A larger sample 
size could help shade clearer associations between having 
DRPs and various potential factors.  
Our study has some limitations. Since the participants 
were in their terminal stage of life, not many of them could be 
available for a certain duration time for investigation. 
Representativeness of this small group of patients was 
somehow problematic, especially after discharge where fewer 
patients were able to attend out-patient and/or home 
healthcare visits. One should be cautious in interpretation on 
the later phase of follow-up. In addition, with the retrospective 
nature of study, some information in the medical records was 
incomplete or lost. Credibility of the results should be of 
caution. Furthermore, different evaluators on DRPs could yield 
different results. This was because the precision on identifying 
DRP was largely based on clinical experience of the 
evaluators. In the future, more prospective studies with 
reasonably long duration and larger sample size and better 
data collection method should be conducted. Such studies 
could offer clearer relationships between DRP and potential 
factors.  
In conclusion, DRPs of opioid analgesics and related 
adjuvant medications among patient end-stage cancer 
receiving palliative care were found. Inconclusive assessment 
on pain and palliative performance made pain management in 
these patients suboptimal. The role of pharmacist in 
multidisciplinary team in palliative care should be encouraged.  
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